Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
Fredrik R. Zetterberg, Alison C. MacKinnon, Thomas Brimert, Lise Gravelle, Richard Johnsson, Barbro Kahl-Knutson, Hakon Leffler, Ulf J. Nilsson, Anders N. Pedersen, Kristoffer Peterson, James A. Roper, Hans Schambye, Robert J. Slack, Susan Tantawi
Abstract
-induced liver fibrosis and bleomycin-induced lung fibrosis mouse models. On the basis of the overall pharmacokinetic, pharmacodynamic, and safety profile, GB1211 was selected as the clinical candidate and is currently in phase IIa clinical trials as a potential therapy for liver cirrhosis and cancer.
Topics & Concepts
BleomycinFibrosisCirrhosisPharmacologyLung cancerIdiopathic pulmonary fibrosisCancer researchChemistryMedicineInternal medicineLungChemotherapyGalectins and Cancer BiologyMacrophage Migration Inhibitory FactorProtein Tyrosine Phosphatases